Risk Factors for Fragility Fractures in Patients with Immunobullous Diseases on Long-term Systemic Glucocorticoids
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Homik J, Suarez-Almazor M, Shea B, Cranney A, Wells G, Tugwell P
. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; (2):CD000952.
PMC: 7046131.
DOI: 10.1002/14651858.CD000952.
View
2.
Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G
. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35.
PMC: 4906542.
DOI: 10.1002/jbmr.2708.
View
3.
Allen C, Yeung J, Vandermeer B, Homik J
. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016; 10:CD001347.
PMC: 6461188.
DOI: 10.1002/14651858.CD001347.pub2.
View
4.
Tee S, Yosipovitch G, Chan Y, Chua S, Koh E, Chan Y
. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2011; 148(3):307-14.
DOI: 10.1001/archdermatol.2011.354.
View
5.
Gedmintas L, Solomon D, Kim S
. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013; 28(8):1729-37.
PMC: 3713078.
DOI: 10.1002/jbmr.1893.
View